CONFIDENTIAL Protocol MT10109L -[ADDRESS_326703] 2018
Original Protocol June 2018
Amendment 4 (September 2020)
This amendment is considered to be nonsubstantial based on the criteria set forth in Article 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council of the European Union 
because it neither significantly  impacts the safety  or phy sical/mental integrity  ofparticipants nor 
the scientific value of the study .
Overall Rationale for the Amendment:
The overall rationale of this protocol amendment was to integrate feedback and
recommendations from a health authority .
Section No. and Nam e Description of Change Brief Rationale
Title Page Updated s ponsor signatory Administrative
[IP_ADDRESS] Primary Analyses Added text describing imputation methods
from the statistical analysis planUpdated per recommendation by [CONTACT_268329]
11 References Added references References added to Section [IP_ADDRESS]
Approval Date: 30-Sep-2020 22:54:58 (GMT)

CONFIDENTIAL Protocol MT10109L -[ADDRESS_326704] of Figures ..................................................................................................................................7
1. Protocol Summary ..........................................................................................................8
1.1. Synopsis ................................ ................................ ................................ ............................ 8
1.2. Schema ............................................................................................................................12
1.3.
Schedule of Activities (SoA) ..........................................................................................13
2.
Introduction...................................................................................................................17
2.1. Study  Rationale ................................ ................................ ................................ ............... 17
2.2. Backgro und.....................................................................................................................17
2.3.
Benefit/Risk Assessment ................................................................................................18
3. Objectives and Endpoints ............................................................................................20
4. Study Design ..................................................................................................................22
4.1. Overall Design ................................ ................................ ................................ ................ 22
4.1.1. Clinical Hy potheses ........................................................................................................23
4.2. Scientific Rationale for Study  Design ............................................................................23
4.3. Justification for Dose ......................................................................................................23
4.4. End of Study  Definition ..................................................................................................24
5. Study Population ...........................................................................................................25
5.1. Inclusion Criteria
................................ ................................ ................................ ............ 25
5.2. Exclu sion Criteria ...........................................................................................................26
Rationale for Inclusion and Exclusion Criteria ..............................................................................28
5.3. Lifesty le Considerations .................................................................................................28
5.4. Screen Failures ................................................................................................................29
6. Study Int ervention ................................ ................................ ................................ ........ 30
6.1. Study  Interventions Administered ................................ ................................ .................. 30
6.1.1. Study  Supplies ................................ ................................ ................................ ................ 30
6.1.2. Instructions for Use and Administration ................................ ................................ ......... 31
6.2. Preparation/Handling/Storage/Accountability ................................................................34
6.3.
Measures to Minimize Bias: Randomization and Blinding................................ ............ 34
6.4. Study  Intervention Compliance ................................ ................................ ...................... 35
6.5. Concomitant Therap y ................................ ................................ ................................ .....35
6.5.1. P rohibited I nterventions ................................ ................................ ................................ ..35
6.5.2. Permitted I nterventions ................................ ................................ ................................ ...36
6.5.3. Rescue Medicine ................................ ................................ ................................ ............. 36
6.6. Dose Modification ................................ ................................ ................................ .......... 37
Approval Date: 30-Sep-2020 22:54:58 (GMT)

CONFIDENTIAL Protocol MT10109L -006 AMD 4
MT10109L
69.4.1. Efficacy  Anal yses................................ ................................ ................................ ........... 52
[IP_ADDRESS]. Primary  Efficacy  Endpoints ...............................................................................52
[IP_ADDRESS]. Primary  Anal yses...............................................................................................52
[IP_ADDRESS]. Secondary  Efficacy  Endpoints ...........................................................................54
[IP_ADDRESS]. Secondary  Anal yses...........................................................................................55
[IP_ADDRESS]. Exploratory  Efficacy  Endpoints .........................................................................56
[IP_ADDRESS]. Exploratory  Efficacy  Analy ses...........................................................................57
9.4.2. Safety  Anal yses...............................................................................................................57
[IP_ADDRESS]. Adverse Events ...................................................................................................57
[IP_ADDRESS]. Vital Signs ..........................................................................................................58
[IP_ADDRESS]. Electrocardiograms .............................................................................................58
[IP_ADDRESS]. Hematology /Chemistry  Laboratory  Testing .......................................................58
9.4.3. Other Anal yses................................................................................................................59
[IP_ADDRESS]. Immunogenicit y Analyses ................................ ................................ .................. 59
9.5. Interim Anal yses.............................................................................................................59
10.
Supporting Documentation and Operational Considerations..................................60
10.1. Appendix 1: Regulatory , Ethical, and Study  Oversight 
Considerations
................................................................................................................61
10.1.1. Regulatory  and Ethical Considerations ...........................................................................61
10.1.2. Financial Disclosure ........................................................................................................61
10.1.3. Informed Consent Process ..............................................................................................62
10.1.4. Data Protection ................................................................................................................62
10.1.5. Posting Clinical Study  Data ............................................................................................62
10.1.6. Data Qualit y Assurance ..................................................................................................63
10.1.7. Source Documents ..........................................................................................................63
10.1.8. Study  and Site Closure ....................................................................................................63
10.1.9. Publication Policy ...........................................................................................................64
10.1.10.
Compliance with Protocol...............................................................................................64
10.2. Appendix 2: Clinical L aboratory  Tests ...........................................................................65
10.3. Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow
-up, and Reporting .........................................................66
Definition of AE ................................ ................................ ................................ ............................ 66
Definition of SAE ................................ ................................ ................................ .......................... 68
Recording and Follow-Up of AEs and/or SAEs................................ ................................ ............ 69
Reporting of SAEs ................................ ................................ ................................ ......................... 70
10.4. Appendix 4: Abbreviations.............................................................................................71
10.5. Appendix 5: Standard Discontinuation Criteria ................................ .............................. 73
10.6. Appendix 6: Study  Tabular Summary ................................ ................................ ............ 75
10.7. Appendix 7: Contraceptive Guidance and Collection of 
Pregnancy  Information ...................................................................................................77
Definitions:
................................ ................................ ................................ ................................ ....77
Contraception Guidance: ................................ ................................ ................................ ............... 77
Pregnancy  Testing:................................ ................................ ................................ ......................... 79
Approval Date: 30-Sep-2020 22:54:58 (GMT)

CONFIDENTIAL Protocol MT10109L -006 AMD 4
MT10109L
131.3. Schedule of Activities (SoA)
All Participants Only Participants Meeting Retreatment CriteriaaAll 
Participants
Study Period ScreeningbRandomization
Treatment
(Day  1)cFollow
-up
(Day  7
and 
Day 
14)Days 
30, 
60, 
90, 
120, 
150Day 
180Days 
210, 
240, 
270, 
300, 
330Retreatment
1 and 
Retreatment 
2 (from Day 
180 through 
Day 330)c,d,eFollow -up
(Day  7 and 
Day 14 after 
each 
retreatment)Follow -up 
(Day 30
after each 
retreatment)eFollow -up 
(Day 90
after each 
retreatment)eEnd of 
Study 
(Day 360 or
Early Exit)
Visit Windows Days −28
to −1- ± 3 
days± 7 
days± 7 
days± 7 
days- ± 3 days ± 7 days ± 7 days ± 7 days
Consent/
AuthorizationX
Dem ographics, 
Weight/ HeightX
Inclusion/
Exclusion 
CriteriaX X
Medical/
Surgical HistoryX
FLO -11©X X X X X X X X X X
FLSQ©
(Baseline)fX
FLSQ (Follow -
up)X X X X X X X X X
Approval Date: 30-Sep-2020 22:54:58 (GMT)

CONFIDENTIAL Protocol MT10109L -[ADDRESS_326705] -T-01-01 v2.0
Note: Participants completing this study through Day 360 will be eligible to enroll into a 2 -year open -label extension study (Study MT10109L -004).
ECG = electrocardiogram; FLO -11=11-item Facial Line Outcomes Questionnaire; FLSQ =Facial Line Satisfaction Questionnaire; FWS =Facial Wrinkle Scale with Photonumeric Guide; 
GL=glabellar lines; LCL = lateral canth al lines (or crow’s feet lines)
a Participants who meet retreatment criteria will receive up to [ADDRESS_326706] be available to the investigator before randomization on Day 1
cAll assessments (including photography and immunogenicity samples, if applicable) must be completed before administration of study intervention.
dRetreatment 1 cannot be administered earlier than the Day 180 visit; Retreatment [ADDRESS_326707]; GL at maximum frown and at rest.
gTo be randomized into the study, participants must meet Inclusion Criterion 2.[ADDRESS_326708] discuss 
compliance with contraceptive use with women of childbearing potential.
lSingle ECG traces will be taken with the participant in a semirecumbent position for ≥ [ADDRESS_326709] be observed for ≥30minutes after each study intervention for adverse events.
Approval Date: 30-Sep-2020 22:54:58 (GMT)

CONFIDENTIAL Protocol MT10109L -006 AMD 4
MT10109L
31Photographic equipment (including headbands and drapes) will be provided by  a qualified 
third- party vendor
Laboratory  sample kits (for immunogenicit yand hematology /chemistry  sampling) will be 
provided b y a qualified third -party vendor
Electroca rdiogram equipment and supplies will be provided by  a qualified third -party vendor
Tablets for electronic PRO administration will be provided b y a qualified third -party vendor
The following will be provided by
 [CONTACT_093]:
Urine pregnancy  test kits (sensitivity  of 25 mIU/mL)
Cotton pads and make- up remover
Appropriatel y sized sterile needles fitted to 1 mL  sterile syringes with 0.01 mL  demarcations 
for extraction of liquid study  intervention from vial
Half-inch 30- gauge sterile needles for stud y inte rvention injection
Alcohol wipes
Protective gloves 
Penlight
Covered container for medical waste (sharps box) 
Refrigerator to store study  intervention with a temperature between 2 °and 8°C
Internet connection (high speed connection for eCRF completion)
Monitor and DVD play er for viewing participant instructions
Centrifuge for separation of serum 
Freezer , that does not automatically  defrost ,to store blood samples at a temperature of −20°C 
or colder
6.1.2.
Instructions for Use and Administration
Only trained and medically  qualified ph ysicians experienced with BoNT/A injections are 
authorized to administer the study  interventions. Study -specific training for L CL and GL 
injections are provided to investigators via a video recording from a board -certified plastic 
surgeon with injection demonstration, and review of injection techniques as outlined in the 
protocol. The video is available on the training portal for injectors to access at any  time as a 
refresher course. The investigator must maintain docum entation of training records for all study  
personnel.
There will be up to [ADDRESS_326710] treatment period ( Day 1 to Day 180), all 
participant s will receive blinded treatment on Day 1, either MT10109L 24U, 44 U, or placebo . 
In the retreatment period ( from Day 180 through Day 330), all participant s will receive up to 
Approval Date: 30-Sep-2020 22:54:58 (GMT)

CONFIDENTIAL Protocol MT10109L -006 AMD 4
MT10109L
322interventions of MT10109L  24U, 44 U, or placebo (same as blinded Treatment 1) based on 
meeting the retreatment criteria.
The L CL study  intervention s will be administered as bilaterall y symmetrical I M injections at 
3injection sites in the lateral aspect of each orbicularis oculi (Figure 6-1A). The GL study  
interventions will be administered as IM injections at 5 injection sites in the glabellar complex , 
2in each corrugator muscle and 1 in the procerus (Figure 6-3A ). Lateral canthal lines and GL 
will be treated together, following the appropriate injection technique for each area, as described 
below.
Participant s must be observed for adverse events for ≥30minutes after each study  intervention.
Lateral Canthal Line Injection Technique
Each injection volume is 0.[ADDRESS_326711] injection will be 
made into the orbicula ris oculi at the level of the lateral canthus, ≥1.5to2.0cm temporal to the 
lateral canthus and just temporal to the lateral orbital rim (Figure 6-1B , Point A ). The second and
third injections will be made 1.[ADDRESS_326712] injection site, each at an 
approximate 30 angle medially . Repeat this procedure for the contr alateral side.
If the lines in the lateral canthal area are primaril y below the lateral canthus, injection sites may  
be given in a line that angles from anteroinferior to superposterior, but the most anterior injection 
willbe lateral to a line drawn vertically  from lateral canthus, and the most inferior injection will
be superior to the maxillary  prominence (Figure 6-2). Repeat this procedure for the contralateral 
side.
Figure 6-1 (A) The Orbicularis Oculi (Lateral Canthal Line Area) on 1 Side of the Face and 
(B)Injection Pattern when Lateral Canthal Lines are Distributed Above and Below the 
Lateral Canthus 
Approval Date: 30-Sep-2020 22:54:58 (GMT)

CONFIDENTIAL Protocol MT10109L -006 AMD 4
MT10109L
346.2. Preparation/Handling/Storage/Accountability
1. The investigator or designee must confirm appropriate temperature conditions have been 
maintained durin g transit for all study  intervention received and an y discrepancies are 
reported and resolved before use of the stud y intervention .
2.Only  participants enrolled in the study  may  receive study  intervention ,and only  authorized 
site 
personnel may administer study  intervention . All study  intervention must be stored in a 
secure, environmentall y controlled, and monitored (manual or automated) area in accordance 
with the labeled storage conditions with access limited to the investigator and authori zed site 
personnel .
3.
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for stud y intervention accountability , reconciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition re cords).
4.Further guidance and information for the final disposition of unused study  interventions are 
provided in the study  manual.
All unused study  intervention and empty  vials must be returned to the sponsor at the termination 
of the study . Unit counts w ill be performed when the study  intervention is returned, and all study  
intervention must be accounted for. Unused drug supplies and empty  vials will be returned to the 
sponsor.
6.3. Measures to Minimize Bias: Randomization and Blinding
At the 
Screening V isit, each participant who provides informed consent will be assigned a 
participant number that will serve as the participant identification number on all study  
documents.
An automated I WRS will be used to manage the randomization and study  intervention
assignment based on a randomization scheme prepared b y the sponsor’s biostatistics department . 
Before administering study  intervention , the 
sitemust contact [CONTACT_941] I WRS and enter the site 
number and the participant’s enrollment stratification information  
The I WRS will then randomly  assign participants to receive 
MT10109L  24U, 44 U, or placebo in a 2:2:[ADDRESS_326713] the I WRS at subsequent retreatment visits (if applicable) to obtain 
study  kit numbers for dispensing study  intervention . Study  sites will receive the I WRS 
confirmation notifications for each transaction
. All notifications are to be maintained with the 
study  source documents.
Approval Date: 30-Sep-2020 22:54:58 (GMT)

CONFIDENTIAL Protocol MT10109L -006 AMD 4
MT10109L
35The I WRS will be programmed with blind- breaking instructions. In case of an emergency , the 
investigator has the sole responsibility  fordetermining if unblinding of a participant’s study  
intervention assignment is warranted. Participant safet y must always be the first consideration in 
making such a determination. I f the investigator decides that unblinding is warranted, the 
investigator s hould make every  effort to contact [CONTACT_1152] a participant’s 
study  intervention assignment unless this could delay  emergency  treatment of the participant. If a 
participant’s stud y intervention assignment is unblinded, the sponsor must be notified within 
[ADDRESS_326714] that specifies the amount of study  
intervention administered to each participant and the date of administration.
6.5. Concomitant Thera py
The use of an y concomitant medication or vaccine (including prescription or over -the-counter
medication, vitamins, and/or 
herbal supplements) is to be recorded on the participant’s e CRF at 
each visit along with the reason the medication is taken.
At scr eening and end of study and upon admission to and discharge from the study  site, study  
sitepersonnel will question each participant specifically  on the use of concomitant medications. 
Study  site personnel must notify  the sponsor immediatel y if a participant consumes any  
concomitant medications not permitted by [CONTACT_760]. Participants who admit to using 
prohibited concomitant medications may  be discontinued from the study  at the discretion of the 
investigator or sponsor.
6.5.1. Prohibited Interventions
The decision to administer a prohibited medication/treatment is done with the safet y of the 
participant as the primary  consideration. When possible, the sponsor must be notified before the 
prohibited medication/treatment is administered. Co -administration of aminogl ycosides or agents 
that could interfere with neuromuscular transmission (eg, curare -like agents) or muscle relaxants 
must be used with caution as the effects of the toxin, theoreticall y, could be potentiated.
No other facial cosmetic procedures or treatments are to be performed throughout the duration of 
the study . Prohibited treatments and procedures include, but are not limited to:
Oral retinoids
New or changes to regimen of topi[INVESTIGATOR_268322]
New or changes to regimen of topi[INVESTIGATOR_268323]
Microdermabrasion to the face
Approval Date: 30-Sep-2020 22:54:58 (GMT)

CONFIDENTIAL Protocol MT10109L -006 AMD 4
MT10109L
36Medium depth to deep facial chemical peels (ie, TCA  and phenol)
Laser treatment, ultrasound treatment , or resurfacing to the face
Facial lift (mid or full face)
Blepharoplasty
Synthetic implantation (eg, Gore -Tex) to the upper half of the face
Autologous fat transplantation to the face
Dermal fillers to the face
Permanent make -up to the face
Concurrent treatment with botulinum toxin of any  seroty pe for any  indication (other than the 
study  intervention ) isprohibited.
6.5.2. Permitted Interventions
Any medication or vaccine ( including prescription or over- the-counter medication, vitamins, 
and/or herbal supplements) that the participant is receiving at the time of enrollment or receives 
during the stud y must be recorded along with:
Indication
Dates of administration including start and end dates
Dosage information including dose and frequency
Therap y considered necessary  for the participant’s welfare may  be given at the discretion of the 
investigator. If the permissibility  of a specific medication/intervention is in question, please 
contact [CONTACT_456].
The sponsor must be contact[CONTACT_268330] y.
Any medication taken during the study  between the date of the first dose of study  intervention 
and the date of the end of study visit will be recorded in the eCRF as a concomitant medication; 
any medicat ion started after the end of study visit will not be considered a concomitant 
medication and should not be captured in the eCRF.
6.5.3. Rescue Medicine
Rescue medicine is not applicable.
Approval Date: 30-Sep-2020 22:54:58 (GMT)

CONFIDENTIAL Protocol MT10109L -006 AMD 4
MT10109L
387. Discontinuation of Study Intervention and Participant
Discontinuation/ Withdrawal
A premature discontinuation will occur if a participant who signs the ICF and is randomized 
ceases participation in the study , regardless of circumstances, before the completion of the 
protocol -defined stud y procedures.
Notification of early  participant d iscontinuation from the study  and the reason for 
discontinuation will be made to the sponsor and will be clearl y documented on the appropriate 
eCRF .
Definitions of the standard terms are provided in Appendix 5 .
Reasons for discontinuation from the study  intervention and/or the study  may  include the 
following commonl y used terms :
Comm only Used T erms
Adverse event
Lost to follow -up
Lack of efficacy
Other
Physician decision
Pregnancy
Protocol deviation
Site terminated by [CONTACT_268331]
7.1. Discontinuation ofStudy Intervention
Study  intervention should be discontinued for the following reasons:
Pregnancy  (see Appendix 7 and Section 8.3.5 )
Other safety  criteria ( eg, hypersensitivity  to the study  intervention , failure to continue to meet 
randomization criteria )
Women who test positive for urine pregnancy  test will NOT receive further treatment and will b e 
discontinued from the study . They  should complete study  exit procedures and be followed up for 
pregnancy
 outcome. See the SoA for data to be collected at the time of intervention 
discontinuation and follow- up an d for any  further evaluations that need to be completed.
Approval Date: 30-Sep-2020 22:54:58 (GMT)

CONFIDENTIAL Protocol MT10109L -006 AMD 4
MT10109L
397.2. Participant Discontinuation/ Withdrawal F rom the Study
A participant may withdraw from the study  at an y time at his/her own request, or may  be 
withdrawn at an y time at the discretion of the investiga torfor safety , behavioral ,compliance, 
or administrative reasons .
If the participant withdraws consent for disclos ure of future information, the s ponsor may  
retain and continue to use any data collected before such a withdrawal of consent .
Seethe SoA for data to be collected at the time of study discontinuation and follow -up and 
for an y further evaluations that need to be completed .
7.3. Lost to Follow Up
A participant will be considered lost to follow -up if he or she repeatedl y fails to return for 
scheduled visits and is unable to be contact[INVESTIGATOR_530] b y the study  site.
The following actions must be taken ifa participant fails to return to the study  site for a required 
study  visit:
The study  site must attempt to contac t the participant and reschedule the m issed visit as soon 
as possible and counsel the participant on the importance of maintaining the assigned visit 
schedule and ascertain whether or not the participant wishes to and/or should continue in the 
study .
Before a participant is deemed lost to follow -up, the investigator or designee must make 
every  effort to regain contact [CONTACT_6635] (where possible, 3 telephone calls and ,if 
necessary ,a certified letter to the participant ’s last known mailing address or local equivalent 
methods). These contact [CONTACT_9145] ’s medical record.
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study.
Discontinuation of specific si tes or of the study  as a whole are handled as part of Appendix 1.
Approval Date: 30-Sep-2020 22:54:58 (GMT)

CONFIDENTIAL Protocol MT10109L -006 AMD 4
MT10109L
408. Study Assessments and Procedures
Study  procedures and their timing are summarized in the SoA. Protocol waiver s or 
exemptions are not allowed.
Immediate safety  concerns should be discussed with the s ponsor immediately  upon 
occurrence or awareness to determine if the participant should continue or discontinue study  
intervention .
Adherence to the stud y design requirement s, including those specified in the SoA, is essential 
and required for stud y conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participant s meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all participant s screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.
The amount of blood collected from each participant throughout this 12 -month study  will be
approximately  220 mL.Repeat or unscheduled samples may  be taken for safet y reasons or 
for technical issues with the samples.
Blood samples may  be stored for a maximum of 5 y ears following finalization of the study ’s 
final CSR. Samples will then be disposed. 
All assessments, including photography , must be completed after the participant removes 
their make -up (if wearing any )and before administration of study  intervention.
8.1. Efficacy Assessments
8.1.1. Facial Wrinkle Scale With Photonumeric Guide (FWS)
Investigators
’and participants’ assessment s of the severit y of LCL at rest and maximum smile
and investigators’ assessments of the severit y of GL at rest and maximum frown usingthe 
validated FWS, based on the following scale:
0 = None
1 = Mild
2 = Moderate
3 = Severe
The FWS with investigator -oriented instructions and the FWS with participant -oriented 
instructions will be provided by  [CONTACT_161697]. Both versions of the FWS provide 
photographic examples of LCL severit y at rest and at maximum 
smile and GLseverit y at rest 
and max imum frown . Prior to enrolling participants, investigators and appropriate site personnel
will be trained in grading LCL and GL severity  using the FWS to ensure that severit y is graded 
consistently  at each site and across all sites.
Approval Date: 30-Sep-2020 22:54:58 (GMT)

CONFIDENTIAL Protocol MT10109L -006 AMD 4
MT10109L
468.3.2. Method of Detecting A dverse Event s and S erious A dverse Events
Care will be taken not to introduce bias when detecting adverse events and/or SAEs . Open -ended 
and nonleading verbal questioning of the participant is the preferred method to inquire about 
adverse event occurrences .
8.3.3. Follow -up of Adverse Events and Serious Adverse Events
After the initial adverse event/SAE report, the investigator is required to proactivel y follow each 
participant who received study  intervention at subsequent visits/contacts. All TEAEs /SAEs , 
including AESIs (see Section 8.3.6 ) willbe followed until resolution, stabiliz ation, the event is 
otherwise explained, or the participant is lost to follow -up (as defined in Sect ion 7.3).
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  
[CONTACT_268332]/or causalit y of the adverse event or SAE as fully  as possible. This may  
include additional laboratory  tests or investigations, histopathological examinations, or 
consultation with other health care professionals.
If a participant dies during parti cipation in the study  or during a recognized follow -up period, the 
investigator will provide the sponsor with a cop y of an y postmortem findings including 
histopathology .
New or updated information will be recorded in the originally  completed eCRF.
The inve stigator will submit any updated SAE data to the sponsor within 24 hours of receipt of 
the information.
8.3.4. Regulatory Reporting Requirements for Serious Adverse Events
Prompt notification by  [CONTACT_11012] a nSAE is essential so that legal 
obligations and ethical responsibilities towards the safet y of participants and the safet y of a 
study  intervention under clinical investigation are met. 
The sponsor has a legal responsibility  to notify  both the local regulatory authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRBs
/IECs, and investigators.
Investigator safety  reports must be prepared for S[LOCATION_003]R saccording to local regulatory  
requirements and sponsor policy  and forwarded to investigators as necessary .
An investigator who receives an investigator safety report describing a nSAE or other 
specific safet y information (eg, summary or listing of SAEs ) from the sponsor will review 
and then file it along with the investigator ’s brochure and will notify  the IRB/IEC, if 
appropriate according to local requirements.
Approval Date: 30-Sep-2020 22:54:58 (GMT)

CONFIDENTIAL Protocol MT10109L -006 AMD 4
MT10109L
48reference safet y information or protocol for the study intervention or comparator as applicable. 
See Section 8.4for information of treatment of overdose.
Underdose: Unintentional administration of a quantity  of the study  intervention given per 
administration or per day that is under the minimum recommended dose according to the 
reference safet y information or p
rotocol. 
8.4. Treatment of Overdose
Overdose of MT10109L is a relative term and depends upon dose, site of injection, and 
underly ing tissue properties. Signs and s ymptoms of overdose are not likel y to be apparent 
immediately  postinjection. Excessive doses may  produce local or distant, generalized and 
profound neuromuscular paral ysis. 
Because MT10109L 
is administered as injections by  [CONTACT_268333] , the chance of 
overdose is extremel y low. Should accidental injection or oral ingestion occur or overdo se be 
suspected, the participant should be medically monitored for up to several weeks for progressive 
signs or s ymptoms of sy stemic muscular weakness that could be local or distant from the site of 
injection, which may  include ptosis, diplopia, dy sphagia, dysarthria, generalized weakness, or 
respi[INVESTIGATOR_33078]. For GL or LCL, ptosis, diplopia, or vision blurred are known local effects of 
the toxin. These participants should be considered for further medical evaluation and appropriate 
medical therap y immediately  instituted, which may  include hospi[INVESTIGATOR_059].
If the musculature of the orophary nx and esophagus is affected, aspi[INVESTIGATOR_268324], which may  
lead to development of aspi[INVESTIGATOR_59499]. If the respi[INVESTIGATOR_268325], intubation and assisted respi[INVESTIGATOR_268326]. Supportive care could involve the need for a tracheostomy  and/or prolonged mechanical 
ventilation, in addition to other general supportive care .
In the event of an overdose, the investigator should educate the participant , monitor the course of 
overdose, contact [CONTACT_268334] y physician as needed, document the quantity  of the excess 
dose, associated adverse events as well as the duration of the overdose in the eCRF .
8.5. Pharmacok inetics
Pharmacokinetic parameters are not evaluated in this study .
8.6. Pharmacodynamics
Pharmacod ynamic parameters are not evaluated in this study .
8.7. Genetics
Genetics are not evaluated in this study .
Approval Date: 30-Sep-2020 22:54:58 (GMT)

CONFIDENTIAL Protocol MT10109L -[ADDRESS_326715] will be provided b y the 
MSP.
The PDSOT will be 
reviewed by[CONTACT_268335] a timely  fashion for monitoring severit y, frequency, 
and trending.
Summary  tables will be provided for participants with SA Es and participants with adverse event s 
leading to discontinuation if 5 or more participants reported such events. Listings of all adverse 
event s, SAEs, and adverse event s leading to discontinuation by  [CONTACT_217664].
The definitions of an adverse event and SAE can be found in Appendix 3 .
[IP_ADDRESS]. Vital Signs
Descriptive summaries (n, mean, SD, median, minimum, and maximum) of actual values and 
changes from baseline will be calculated for vital signs (s ystolic and diastolic blood pressure, 
pulse and respi[INVESTIGATOR_1487]). These summaries will be presented b y study intervention and b y visit.
[IP_ADDRESS]. Electrocardiograms
Descriptive statistics for ECG parameters (eg, heart rate, QRS duration, QT interval, QTc
intervals, RR interval, and PR interval) at baseline, and changes from baseline at all postbaseline 
timepoints will be presented by [CONTACT_268336]. For each parameter, onl y 
participant s who had both baseline postbaseline assessments will be included in the summary . 
QTc interval will be calculated using both Bazett (QTcB = QT/ [RR
]½) and Fridericia 
(QTcF = QT/[RR]⅓) corrections; if RR is not available, it will be replaced with 60/heart rate in 
the correction formula. 
Data listings , which include ECG basic parameters and ECG abnormalities, will be produced.
[IP_ADDRESS]. Hematology/Chemistry Laboratory Testing
Descriptive statistics (n, mean, SD, median, minimum, and maximum) for clinical laboratory  
values at baseline and change from base line at postbaseline visits will be summarized in SI  units 
by [CONTACT_268336].
Approval Date: 30-Sep-2020 22:54:58 (GMT)

CONFIDENTIAL Protocol MT10109L -006 AMD 4
MT10109L
599.4.3. O ther Analyses
[IP_ADDRESS]. Immunogenicity Analyses
Immunogenicit y results, manifested as the presence of binding antibodies and neutralizing 
antibodies to MT10109L, will be summarized in a table .
9.5. Interim Analyses
No interim anal ysis is planned.
Approval Date: 30-Sep-2020 22:54:58 (GMT)

CONFIDENTIAL Protocol MT10109L -006 AMD 4
MT10109L
6010. Supporting Documentation and Operational Considerations
Approval Date: 30-Sep-2020 22:54:58 (GMT)

CONFIDENTIAL Protocol MT10109L -006 AMD 4
MT10109L
6110.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following :
oC
onsensus ethic alprinciples derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences 
(CIOMS) International Ethical Guidelines
oApplicable ICH /ISOGCP guidelines
oApplicable laws and regulations
The protocol, protocol amendments, I CF, investigator ’s b rochure, and other relevant 
documents (eg, advertisements) must be submitted to an I RB/IEC by  [CONTACT_268337]/IEC before the study  is initiated. 
Any amendments to the protocol will require IRB/I EC approval before implementation of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants. 
The investigator will be responsible for the following:
oProviding written summaries of the status of the study to the IRB/ IEC annually  or more 
frequentl y in accordance with the requirements, policies, and procedures established by 
[CONTACT_1201]/IEC
oNotify ing the IRB/IEC of SAE sor other significant safet y findings as required by 
[CONTACT_1744]/IEC procedures
oProviding oversight of the overall conduct of the study  at the site and adherence to 
requirements of applicable local regulations, for example 21 C FR, I CH guidelines, the 
IRB/IEC, and European regulation 536/2014 for clinical studies (if applicable)
10.1.2. Financial Disclosure
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow th e sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities. I nvestigators are 
responsible for providing information on financial interests during the course of the stud y and for 
1 year after completion of the study .
Approval Date: 30-Sep-2020 22:54:58 (GMT)

CONFIDENTIAL Protocol MT10109L -006 AMD 4
MT10109L
6210.1.3. Informed Consent Process
The investigator or his/her representative will explain the nature of the study to the 
participant or his/her legally  authorized representative and answer all questions regarding the 
study . 
Participants must be informed that their participation is voluntary . Participants will be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 50, 
local regulations, ICH guidelines, HI PAA requirements, where applicable , and the IRB/IEC 
or study  center . 
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study and the date the written consent was obtained. 
The authorized person obtaining the infor med consent must also sign the ICF .
Participants must be reconsented to the most current version of the ICF(s) during their 
participation in the study . 
A copy of the ICF(s) must be provided to the participant or the participant’ s legall y 
authorized repres entative. 
Participants who are rescreened are required to sign a new ICF.
10.1.4. Data Protection
Participants will be assigned a unique identifier. Any participant records or datasets that are 
transferred to the sponsor will contain the identifier only ; particip ant names or an y 
information which would make the participant identifiable will not be transferred. 
The participant must be informed that his/her personal study -related data will be used by  [CONTACT_20004] . The lev el of disclosure must also be 
explained to the participant. 
The participant must be informed that his/her medical records may  be examined by  [CONTACT_268338] b y the sponsor , by 
[CONTACT_6667]/IEC members, and by  [CONTACT_90742].
10.1.5. Posting Clinical Study Data
Study  data and information may  be published in nonpromotional, peer -reviewed publications 
either b y or on behalf of the sponsor . 
Clinical study  reports, safety  updates, and annual reports will be provided to regulatory  
authorities as required.
Company -sponsored study  information and tabular study  results will be po sted on the US 
National Institutes of Health’ s website www .ClinicalT rials.gov and other publicly  accessible 
sites.
Approval Date: 30-Sep-2020 22:54:58 (GMT)

CONFIDENTIAL Protocol MT10109L -006 AMD 4
MT10109L
6510.2. Appendix 2: Clinical Laboratory Tests
The tests detailed in Table10-1will be performed by  [CONTACT_2237] . 
Protocol -specific requirements for inclusion or exclusion of participants are detailed in 
Section 5 of the protocol.
Additional tests may  be performed at an y time during the stud y as determined necessary  by 
[CONTACT_43215]
.
Table 10-1 Protocol -Required Safety Laboratory Assessments
Laboratory 
AssessmentsParam eters
Hem atology Platelets
RBC count
Hem oglobin
Hem atocrit
RBC morphologyWBC count with differential (absolute) :
Neutrophils
Lymphocytes
Monocytes
Eosinophils
Basophils
Clinical 
ChemistryBUN
Potassium
AST
Total, direct and indirect bilirubin
Creatinine
Sodium
ALT
Total proteinGlucose
Calcium
Alkaline phosphatase
Chloride, albumin
Magnesium
Phosphorus
Bicarbonate (carbon dioxide content)
Uric acid
Investigators must document their review of each laboratory  safet y report.
Approval Date: 30-Sep-2020 22:54:58 (GMT)

CONFIDENTIAL Protocol MT10109L -[ADDRESS_326716] lower limit of normal value provided b y the laboratory
MCMC Markov chain Monte Carlo
mITT modified intent- to-treat
MSP medical safety  physician
PDSOT possible distant spread of toxin
PRO patient -reported outcome
RBC red blood cell
SAE serious adverse event
SAP statistical analy sis plan
SI Le Système International d’Unités (Internat ional Sy stem of Units)
SoA schedule of activities
S[LOCATION_003]R serious adverse reactions
TCA trichloroacetic acid
U unit
UFL upper facial lines
ULN upper limit of normal value provided b y the laboratory
WBC white blood cell
WOCBP woman of c hildbearing potential
Approval Date: 30-Sep-2020 22:54:58 (GMT)

CONFIDENTIAL Protocol MT10109L -[ADDRESS_326717] to the 
guidelines set out by [CONTACT_760] (NCI)
Recovery A healing process and/or an outcome implying 
relative health. The term is typi[INVESTIGATOR_268327]. (NCI)
Screen failure The potential subject who does not meet one or 
more criteria required for participation in a trial
Site terminated by [CONTACT_78588] a clinical study was stopped at 
a particular site by [CONTACT_110039] s ponsor (NCI)
Study terminated by [CONTACT_78588] a clinical study was stopped by 
[CONTACT_23662] (NCI)
Technical problems A problem with some technical aspect of a 
clinical study, usually related to an instrument 
(NCI)
Withdraw al by [CONTACT_7078]/guardian An indication that a study participant has been 
removed from the study by [CONTACT_268339] a study participant has 
removed itself from the study (NCI)
Approval Date: 30-Sep-2020 22:54:58 (GMT)

CONFIDENTIAL Protocol MT10109L -006 AMD 4
MT10109L
78Table 10-2 Highly Effective Contraceptive Methods
Highly Effective Contraceptive Methods That Are User Dependenta
Failure rate of < 1% per year when used consistently and correctly
Com bined (estrogen -and progestogen -containing) hormonal contraception associated with inhibition of ovulation 
Oral 
Intravaginal 
Transdermal 
Progestogen -only hormonal contraception associated with inhibition of ovulation
Oral 
Injectable 
Highly Effective Methods That Are User Independenta
Implantable progestogen -only hormonal contraception associated w ith inhibition of ovulation
IUD
IUS
Etonogestrel implant (ie, Nexplanon®)
Bilateral tubal occlusion
Intrauterine copper contraceptive (ie, ParaGard®)
Vasectom ized Partner 
A vasectomized partner is a highly effective contraception method provided that the partner is the sole male 
sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective 
method of contraception should be used.
Sexual Abstinence 
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study intervention. The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of 
the participant.
aTypi[INVESTIGATOR_35818]. Use should be consistent 
with local regulations regarding the use of contraceptive methods for participants participating in clinical 
studies. 
Table 10-3 Acceptable Contraceptive Methods
Acceptable Methods
Acceptable birth control methods that result in a failure of more than 1% per year include:
Progestogen -only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action
Male or female condom with or without spermicide 
Cap, diaphragm, or sponge with spermicide
Nonhormonal intrauterine device
A combination of male condom with either cap, diaphragm, or sponge with spermicide (double barrier m ethods) 
are also considered acceptable, but not highly effective, birth control methods.
Approval Date: 30-Sep-2020 22:54:58 (GMT)

Approval Date: 30-Sep-2020 22:54:58 (GMT)

Approval Date: 30-Sep-2020 22:54:58 (GMT)

Approval Date: 30-Sep-2020 22:54:58 (GMT)

Approval Date: 30-Sep-2020 22:54:58 (GMT)

Approval Date: 30-Sep-2020 22:54:58 (GMT)

Approval Date: 30-Sep-2020 22:54:58 (GMT)

Approval Date: 30-Sep-2020 22:54:58 (GMT)

Approval Date: 30-Sep-2020 22:54:58 (GMT)

Approval Date: 30-Sep-2020 22:54:58 (GMT)

Approval Date: 30-Sep-2020 22:54:58 (GMT)

Approval Date: 30-Sep-2020 22:54:58 (GMT)

Approval Date: 30-Sep-2020 22:54:58 (GMT)

Approval Date: 30-Sep-2020 22:54:58 (GMT)

CONFIDENTIAL Protocol MT10109L -006 AMD 4
MT10109L
102Section No. and Name [CONTACT_268340] 7 (Table 10 -3) Added text to include as one of the acceptable 
birth control methods the option of male or 
female condoms without spermicide (in 
addition to male or female condoms with 
spermicide)Correction
Throughout Mino r editorial revisions Minor, therefore 
have not been 
summarized
Approval Date: 30-Sep-2020 22:54:58 (GMT)

CONFIDENTIAL Protocol MT10109L -006 AMD 4
MT10109L
[ZIP_CODE]. References
Beer KR. Comparative evaluation of the safety  and efficacy  of botulinum toxin ty pe A and 
topi[INVESTIGATOR_268328] -to-severe glabellar rhy tids. Dermatol Surg. 
2006;32:1 84-192.
Blitzer A, Brin MF, Keen MS, Aviv JE. Botulinum toxin for the treatment of hy perfunctional 
lines of the face. Arch Otolary ngol Head Neck Surg. 1993;119:1018 -
1022.
BOTOX®Cosmetic (onabotulinumtoxinA ) for injection [package insert]. Irvine, CA: Allergan, 
Inc; 
October 2017.
Brin MF, Boodhoo TI, Pogoda JM, James L M, Demos G, Terashima Y, et al. Safet y and 
tolerability  of onabotulinumtoxinA in the treatment of facial lines: A meta
-analysis of individual 
patient data from global clinical registration studies in 1678 participants. J Am Acad Dermatol. 
2009;61:961 -970. e1- 11.
Dmitrienko A, Molenberghs G, Chuang
-Stein C, Offen W. Gatekeepi[INVESTIGATOR_254560]. In: Analy sis 
of Clinical Trials Using SAS: A Practical Guide. SAS I nstitute; Cary , North Carolina: 
2005;104-108.
Finn CJ, Cox SE, Earl ML. Social implications of hy perfunctional facial lines. Dermatol Surg. 
2003;29:450 -455.
Farage MA, Miller KW, Berardesca E, Maibach HI. Psy chological and Social I mplications of 
Aging Skin: Normal Aging and the Effects of Cutaneous Disease. In: Farage MA, Miller KW, 
Maibach HI, editors. Textbook of Aging Skin. Springer; [LOCATION_001], [LOCATION_001]: 2010;949-958.
Ferreira MC, Salles AG, Gimenez R, Soares MFD. Complications with the use of b otulinum 
toxin ty pe A in facial rejuvenation: report of [ADDRESS_326718] Surg. 2004;28:441 -
444.
Garcia A, Fulton JE Jr. Cosmetic denervation of the muscles of facial expression with botulinum 
toxin: A dose -response study . Dermatol Surg. 1996;22:39
-43. 
Khan JA. Aesthetic surgery : Diagnosing and healing the miscues of human facial expression. 
Ophthal Plastic Reconstr Surg. 2001;17:4 -6.
Koblenzer CS. Psy chologic aspects of aging and the skin. Clin Dermatol. 1996;14:171 -177.
O'Kelly  M, Ratitch B. Clinica l trials with missing data: 
Aguide for practitioner . Statistics in 
Practice. 
Wiley s;2014.
Wilson EB Hilferty , MM. The distribution of chi -squared. Proceedings of the National Academ y 
of Sciences, Washington. 1931;17:12,684–688.
Approval Date: 30-Sep-2020 22:54:58 (GMT)

Electronic Signatures
User Date Justification
Approval Date: 30-Sep-2020 22:54:58 (GMT)
